Brief: Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
01/06/2026 12:32
BRIEF-Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany June 1 (Reuters) - Cytokinetics Inc CYTK.O:
CYTOKINETICS - MYQORZO LAUNCHED IN GERMANY FOLLOWING EUROPEAN COMMISSION APPROVAL IN FEBRUARY 2026
Source text: ID:nGNE72kD5m
Further company coverage: CYTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytokinetics, Incorporated
See all newsBrief: Cytokinetics To Announce Third Quarter Results On November 4, 2026
Brief: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Cytokinetics Announces Additional Data From Acacia-Hcm Presented At The Hfsa Annual Scientific Meeting 2026
Brief: Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy
U.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech